Novartis’ meningitis B vaccine wins breakthrough therapy status in U.S.

[Reuters] – Novartis said U.S. health regulators have granted the Swiss drugmaker’s meningitis B vaccine Bexsero breakthrough therapy status. Bexsero is widely seen as crucial to Novartis’ vaccines business, which has struggled to catch market leaders Gl more

View todays social media effects on NVS

View the latest stocks trending across Twitter. Click to view dashboard

See who Novartis is hiring next, click here to view